Prescription drug price transparency; manufacturer reporting requirements.
Impact
If enacted, this legislation would amend existing Virginia statutes related to drug pricing by mandating annual disclosures from drug manufacturers. This increased transparency is intended to help consumers, healthcare providers, and policymakers better understand the factors affecting prescription drug prices. With the specified reporting obligations, manufacturers contributing to increases in the wholesale acquisition costs of essential medications would need to justify their actions, which may lead to more competitive pricing in the long term.
Summary
House Bill 2233 aims to enhance prescription drug price transparency by imposing reporting requirements on manufacturers concerning specific drugs. Under the bill, manufacturers must report annually to a designated nonprofit organization information about the wholesale acquisition costs of brand-name drugs, biologics, and certain generic drugs. The report must include data on price increases, research and development costs, and other significant regulatory compliance metrics, thereby promoting accountability regarding drug pricing amidst rising healthcare costs.
Contention
There may be contention surrounding HB2233 regarding the balance between corporate interests and public health initiatives. Supporters argue that the bill is necessary for fostering competition among drug manufacturers and alleviating healthcare costs for consumers. Conversely, opponents might express concerns about the feasibility of compliance for smaller manufacturers or the potential administrative burdens placed on drug companies, which could adversely affect innovation and drug availability. The legislative discussions may highlight differing viewpoints on how transparency could impact the pharmaceutical market.
Pharmacy benefit managers and health carriers required to include lower-cost drugs in their formularies, and formulary structure and formulary tiering for each health plan required to give preference to the drug with the lowest out-of-pocket cost to the patient.
Pharmacy benefit managers and health carriers inclusion of lower-cost drugs in formularies requirement provision and lowest out-of-pocket-cost drug to patient formulary tiering preference provision
Health: pharmaceuticals; drug manufacturers from engaging in certain conduct with pharmacies participating with a 340B program; prohibit. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 17757c. TIE BAR WITH: SB 95'25
Human services: medical services; Medicaid managed care contract with pharmacy benefit manager; modify. Amends sec. 105i of 1939 PA 280 (MCL 400.105i).